MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4244/eij-d-25-00423

Медицинская библиотека · EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025

TRICURE: first-in-human study of the Topaz transcatheter tricuspid heart valve system.

Teiger Emmanuel, Nejjari Mohammed, Rosseel Liesbeth, Kefer Joëlle, Verheye Stefan, Lancellotti Patrizio, Oliver Léopold, Obadia Jean-François, Asch Federico M, Blanke Philipp, Dreyfus Julien

Клиническое исследованиеСтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Given the poor prognosis of tricuspid regurgitation (TR) patients, there is growing interest in addressing TR, particularly since the emergence of novel transcatheter tricuspid valve interventions for patients at high risk for surgery.

AIMS: The TRICURE first-in-human (FIH) study evaluates the initial feasibility and clinical safety of the Topaz transcatheter tricuspid valve replacement (TTVR) system in treating TR. Featuring a novel dual-stent design, the system is specifically engineered for the unique anatomy of the tricuspid valve. It has a flexible outer stent with low radial force designed to accommodate annular dynamics and conform to the non-circular, variable shapes of the tricuspid valve, coupled to a rigid inner stent aiming to maintain valve function integrity.

METHODS

TRICURE FIH is a prospective, multicentre, first-in-human study with follow-up extending to 5 years. The primary safety endpoint is a composite measure including all-cause mortality, heart failure rehospitalisation, and reintervention for failed tricuspid therapy at 30 days. The primary performance endpoint is device success, defined as a TR reduction ≥1 grade with no more than moderate TR post-procedure.

RESULTS

A total of 20 patients were enrolled. The procedure time (from delivery system insertion to removal) was 35±16 minutes. At 30 days, the primary safety endpoint, a composite of major adverse events, was observed in 35%, and the primary performance endpoint was successfully achieved in all patients (100%), with all patients having a TR reduction of at least 3 grades, and none of the patients having more than mild TR post-procedure. No device-related pacemaker implant was reported. An exemplary case report demonstrates complete elimination of TR and a reverse remodelling of the right ventricle of 19% at 6 months.

CONCLUSIONS

The TRICURE FIH study provides evidence of the feasibility and safety of a novel TTVR system. Outcomes need to be confirmed in a larger series. (ClinicalTrials.gov: NCT05126030).

Для цитирования: Teiger Emmanuel, Nejjari Mohammed, Rosseel Liesbeth, Kefer Joëlle, Verheye Stefan, Lancellotti Patrizio, Oliver Léopold, Obadia Jean-François, Asch Federico M, Blanke Philipp, Dreyfus Julien. TRICURE: first-in-human study of the Topaz transcatheter tricuspid heart valve system.. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2025. DOI: 10.4244/eij-d-25-00423.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.